IFN alpha-IFNAR-IN-1

IFN alpha-IFNAR-IN-1

• CAS Number: 844882-93-5
• UNSPSC Description: IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR; inhibit MVA-induced IFN-α responses by BM-pDCs (IC50=2-8 uM). IC50 value: Target: IFN alpha-IFNAR interaction inhibitor IFN alpha-IFNAR-IN-1 specifically inhibits MVA-induced IFN-α responses by BM-pDCs. IFN alpha-IFNAR-IN-1 inhibited the IFN-α responses that were elicited after treatment with CpG2216, stimulation with poly(I:C), and infection with VSV-M2, whereas the total IL-12 production was notably less affected under those conditions. IFN alpha-IFNAR-IN-1 exerts immunosuppressive activity by the direct interaction with IFN-α [1].
• Target Antigen: IFNAR
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/IFN-alpha-IFNAR-IN-1.html
• Solubility: 10 mM in DMSO
• Smiles: CNCC1=CC=CC=C1SC2=C(C=CC=C3)C3=CC=C2
• Molecular Weight: 279.40
• References & Citations: [1]Geppert T, et al. Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions. Angew Chem Int Ed Engl. 2012 Jan 2;51(1):258-61.Arthritis Rheumatol. 2020 Jun;72(6):1003-1012.|Cell Rep. 2022 Nov 29;41(9):111738.|Free Radic Biol Med. 10 October 2022.|Front Immunol. 2019 May 3;10:980.|Sci Rep. 2016 Jul 14;6:29665.|Adv Healthc Mater. 2023 Jan 30;e2202830.|Arthritis Res Ther. 2022 Jul 19;24(1):170.|Cell Death Dis. 2020 Dec 11;11(12):1050.|Cell Mol Life Sci. 2022 Jan 20;79(2):83.|Cell Rep. 2023 Feb 28;42(3):112145.|Cell Rep. 2024 Apr 23;43(4):114088.|Clin Exp Immunol. 2020 Dec 23.|Exp Eye Res. 2021 Jan;202:108375.|Front Immunol. 2019 Oct 11;10:2391.|J Med Virol. 2023 Nov 7.|Mol Oncol. 2023 Sep 25.|Nature. 2022 Sep;609(7928):785-792.|Pharmacol Res. 2022 Dec 16;187:106615.|PLoS Pathog. 2022 Feb 14;18(2):e1010301.|Viruses. 2022, 14(8), 1806.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported